Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor memory T cells
- Development stage
- Preclinical
- Lead developer
- GenScript
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous tumor memory T cells (GS-T03) is an ex vivo expanded cell therapy being developed by Shanghai East Hospital for the treatment of solid tumors, including lung cancer and malignant pleural mesothelioma. The therapeutic involves isolating T cells from a patient's malignant pleural effusion and activating them using a proprietary nanodiamond-based artificial antigen-presenting cell (APC) system. This 14-day manufacturing process is designed to generate a population of memory T cells with enhanced anti-tumor cytotoxicity, high purity, and improved persistence. The program is currently undergoing in vitro validation and laboratory-based characterization to assess its potential for treating malignant pleural effusions associated with advanced cancers.
- Other names
- autologous memory T cells from pleural effusionnanodiamond APC-activated autologous tumor memory T cells
02
Targets
MUC1-HLA (Mucin 1 peptide–Human leukocyte antigen complex)Human epidermal growth factor receptor 2 peptide–Human leukocyte antigen complex (HER2 peptide–HLA complex)Tumor-associated antigen peptide-human leukocyte antigen complex (TAA-HLA complex)
Beyond the preview
Go deeper on autologous tumor memory T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor memory T cells.